scholarly journals Recommendations on Management of Latent Tuberculosis Infection in Patients Initiating Anti-tumor Necrosis Factor Biologics

2021 ◽  
pp. 1-7
Author(s):  
Cecilia Kit Ying O’Young ◽  
King Man Ho ◽  
Ho So ◽  
Thomas Yun Wing Mok ◽  
Chi Chiu Leung ◽  
...  
Keyword(s):  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Latent Tuberculosis Infection ◽  
Inflammatory Diseases ◽  
Scientific Evidence ◽  
Latent Tuberculosis ◽  
Tuberculosis Infection ◽  
Increased Risk ◽  
Screening Protocol ◽  
Necrosis Factor

Patients with immune-mediated inflammatory diseases on anti-tumor necrosis factor (TNF) agents are at increased risk of developing active tuberculosis (TB). Screening and treatment of latent tuberculosis infection (LTBI) with the use of a standard screening protocol is important in reducing the risk of TB reactivation during therapies with anti-TNF agents. The Latent Tuberculosis Infection Working Group under the Tuberculosis Control Coordinating Committee of the Department of Health and the Hospital Authority has reviewed and assessed local and international scientific evidence and formulated guideline statements on the management of LTBI in patients initiating anti-TNF biologics.

Challenges in Diagnosing Latent Tuberculosis Infection in Patients Treated with Tumor Necrosis Factor Antagonists

2011 ◽  
Vol 38 (7) ◽  
pp. 1234-1243 ◽  
Author(s):  
EDWARD C. KEYSTONE ◽  
KIM A. PAPP ◽  
WENDY WOBESER
Keyword(s):  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Latent Tuberculosis Infection ◽  
Inflammatory Diseases ◽  
Diagnostic Testing ◽  
False Negative ◽  
Latent Tuberculosis ◽  
Tuberculosis Infection ◽  
Tnf Α ◽  
Necrosis Factor

Reactivation of latent tuberculosis infection (LTBI) is well recognized as an adverse event associated with anti-tumor necrosis factor-α (anti-TNF-α) therapy. The strengths and weaknesses of current techniques for detecting LTBI in patients with chronic inflammatory diseases such as rheumatoid arthritis (RA) and psoriasis have not been fully examined. T cell hyporesponsiveness due to immunosuppression caused by illness or drugs, referred to as anergy, may produce false-negative tuberculin skin test (TST) and interferon-γ release assay (IGRA) results. The literature suggests that anergy may influence screening performance of TST and IGRA tests in candidates for anti-TNF-α therapy. Conversely, the potential for false-positive TST and IGRA results must be considered, as treatment for LTBI may be associated with significant morbidity. This review examines the reliability issues related to LTBI diagnostic testing and provides practical direction to help prevent LTBI reactivation and facilitate successful anti-TNF-α treatment.

scholarly journals Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists

2005 ◽  
Vol 52 (6) ◽  
pp. 1766-1772 ◽  
Author(s):  
Loreto Carmona ◽  
Juan J. Gómez-Reino ◽  
Vicente Rodríguez-Valverde ◽  
Dolores Montero ◽  
Eliseo Pascual-Gómez ◽  
...  
Keyword(s):  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Latent Tuberculosis Infection ◽  
Latent Tuberculosis ◽  
Tuberculosis Infection ◽  
Tumor Necrosis Factor Antagonists ◽  
Necrosis Factor
Sign in / Sign up

Export Citation Format

Share Document